MedTrace Logo

Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine

NCT01815073 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 497

Last updated 2014-02-24

No results posted yet for this study

Summary

The purpose of this study is to observe the occurrence of adverse events and seroconversion rate, geometric mean titres (GMTs) of live attenuated varicella vaccine，live attenuated JE vaccine and live attenuated varicella vaccine combined with live attenuated JE vaccine, respectively.

Conditions

  • Japanese Encephalitis
  • Chickenpox

Interventions

BIOLOGICAL

Live Attenuated Varicella Vaccine + Live Attenuated JE Vaccine

BIOLOGICAL

Live Attenuated Varicella Vaccine

BIOLOGICAL

live attenuated JE vaccine

Sponsors & Collaborators

  • Guangdong Provincial Institute of Biological Products And Materia Medica

    collaborator OTHER

  • Changchun Keygen Biological Products Co., Ltd.

    lead OTHER

Principal Investigators

  • Zheng Huizhen, Master · Guangdong Center for Disease Prevention and Control

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
3 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2013-07-31
Completion
2013-07-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01815073 on ClinicalTrials.gov